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Heart valve calcification and calcium x phosphorus product VC is strongly associated with myocardial and coronary
in hemodialysis patients: Analysis of optimum values for its calcification in dialyzed patients [6, 7].
prevention. Several factors have been reported to explain the
Background. Prevalence of valve calcification (VC) in end-
higher prevalence of VC in the maintenance HD popula-stage renal disease (ESRD) patients is high and information
tion. Hemodynamic alterations associated with the ure-regarding modifiable predictors is scarce. Our aim was to deter-
mic state, or the dialysis procedure itself may lead tomine the prevalence of VC in our maintenance hemodialysis
(HD) population, and the optimal Ca x P value that most repetitive mechanical stress and local inflammation that
accurately predicted the presence of VC after controlling for may well promote the initiation of calcification [1]. Fur-
comorbidities. thermore, dyslipidemia and a high calcium phosphorus
Methods. This was a cross-sectional observational study of
product (Ca x P) have been related with dysthrophica cohort of 52 stable patients on maintenance HD for more than
soft tissue calcification and cardiovascular mortality in12 months. Mean 12 months serum biochemical data (calcium,
phosphorus, PTH, lipids) and M-mode 2D echocardiogram ESRD patients [5, 8–11].
were used to evaluate the presence or absence of mitral and The aim of the present study was to determine the
aortic VC and ventricular geometry. prevalence of VC in our maintenance HD population
Results. Twenty patients (38.4%) presented with VC. Pa- and to establish the optimal Ca x P value that mosttients with VC were more commonly diabetic and showed
accurately predicted VC after controlling for comorbid-higher levels of serum phosphorus, Ca x P product, total and
ities.LDL cholesterol, and poor ventricular geometry, as compared
to patients without VC. Moreover, they required higher doses
of both CaCO3 and Al(OH)3. Logistic regression analysis
METHODSshowed that VC was independently influenced by age, Ca x P,
and diabetes. ROC curves illustrated that a Ca x P 43 mg2/dL2 We performed a cross-sectional study of a cohort of
was the optimal value in terms of sensitivity and specificity for
52 patients on maintenance HD for more than 12 monthspredicting the presence of VC in our patient population.
(59.7  15.6 years, 63% men, 54% diabetics, time onConclusion. These findings highlight the importance of
maintenance HD 20.5 17.9 months). All patients wereapplying more vigorous measures for Ca x P control.
in steady clinical condition, on thrice-weekly 3.5 to 4.5
hours of standard bicarbonate hemodialysis, with a pre-
scribed urea reduction 65%. Patients were managedThe prevalence of valve calcification (VC) in mainte-
according to a standardized protocol.nance hemodialysis (HD) patients is eightfold more than
An echocardiogram was performed at enrollment andthat found in their counterparts in the general population
the prior mean 12-month values of serum calcium, phos-(40% vs. 5%) [1, 2], and evolves rapidly from subclinical
phorus, PTH (IRMA, Nichols Institute, CA, USA), cho-to severe dysfunction within a few years [3–5]. In adition,
lesterol, triglycerides, and HbA1C (glycated hemoglo-
bin) were recorded. Mean daily oral calcium intake from
CaCO3, the number of hypercalcemia episodes (11Key words: valve calcification, calcium phosphorus product, mainte-
nance hemodialysis. mg/dL), the proportion of patients on Al(OH)3 and cal-
citriol therapy were also recorded. 2003 by the International Society of Nephrology
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Table 1. Demographic, biochemical and echocardiographic parameters in patients with and without VC
Total With VC Without VC P value
No. patients % 52 20 (38.4) 32 (61.6)
Gender M/F 33/19 15/5 18/14 0.24
Age years 59.715.6 63.413.9 57.516.4 0.17
Time on HD months 20.57.9 20.518.2 20.518 0.98
Diabetics % 53.8 75 40.6 0.01
IVS mm 14.43.3 16.63.2 13.42.9 0.002
LVM g 263.184.7 319.275.3 237.977.3 0.004
LVMI g/m2 151.447.5 175.744.7 140.545.2 0.02
LVH % 66.6 77 62 0.24
Systolic blood pressure mm Hg 138.913.2 142.49.6 137.0514.7 0.18
Serum calcium mg/dL 9.50.5 9.60.6 9.40.5 0.48
Serum phosphorus mg/dL 4.81.4 5.71.3 4.31.1 0.0001
Ca x P mg2/dL2 46.213.1 54.511.7 41.0411.3 0.0001
iPTH pg/mL 168166.9 232.2231.8 127.391.3 0.07
Hypercalcemic episodes 0.741.12 0.81.2 0.20.5 0.052
Total cholesterol mg/dL 175.637.1 188.743.9 167.529.9 0.04
Triglicerides mg/dL 153.968.3 168.972.7 144.264.7 0.22
LDL-cholesterol mg/dL 87.832.3 100.633.9 79.328.8 0.02
Albumin g/dL 3.70.2 3.70.2 3.70.3 0.98
HbA1C % 6.54.7 6.072.09 6.75.9 0.56
Ca binder dose mg/day 1209768 1551728 988720 0.01
Patients on Al(OH)3 therapy % 30.8 60% 12.5% 0.001
Patients on calcitriol therapy % 42.3 55% 34.3% 0.14
Abbreviations are: IVS, interventricular septum; LVM: left ventricular mass; LVMI, left ventricular mass index; LVH, left ventricular hypertrophy; VC, valve
calcification.
Table 2. Stepwise logistic regression analysis modelsUltrasonography
of independent predictors for VC
An M-mode two-dimensional echocardiogram was
Model 1 Model 2carried out to evaluate the presence or absence of mitral
Age y 1.14 (1.02–1.26) 3.61 (0.74–17.49)and aortic VC. Left ventricular geometry was measured
P  0.014 P  0.1
following recommendations of the American Society of Ca x P 1.21 (1.08–1.36) Not included
P  0.0001Echocardiography [12, 13].
Serum phosphorus Not included 6.83 (1.33–34.96)
P  0.02Statistical analysis
Hypercalcemic episodes NS 10.41 (1.68–64.32)
P  0.01All data are expressed as mean  SD. Characteristics
Diabetes 4.4 (1.27–15.05) 6.32 (1.32–30.3)of the two groups were compared by two-tailed unpaired
P  0.02 P  0.02
t test (continuous variables) or Chi-square test (categori-
Model 1 includes the covariates that were significant predictors in the univari-cal variables). Stepwise logistic regression analysis was ate model. In Model 2, serum phosphorus substituted Ca x P. The table shows
odds ratio (95% confidence interval) and P values.performed with VC as the dependent variable. The opti-
mal Ca x P value associated with the absence of VC
was assessed by receiver-operator characteristic (ROC)
curve. The best discrimination limit for Ca x P level was
and LDL cholesterol. In addition, this group requireddetermined at the maximun of the Youden’s index: J 
higher doses of CaCO3 and Al(OH)3 for phosphorussensitivity  specificity – 1. Significant differences were
control. Finally, parameters of ventricular geometrydefined as P  0.05. Statistical analysis was performed
were more disturbed in the VC group.using the SPSS 10.0 for Windows (SPSS, Inc., Chicago,
A subanalysis of diabetic patients showed similar sta-IL, USA); the NCSS 2000 (Kaysville, UT) and the Log-
tistical differences between patients with and withoutxact software (Cytel, MA, USA) were used for exact
VC (data not shown).logistic regression analysis.
In order to determine the predictors of VC (dependent
variable), a stepwise logistic regression analysis was per-
RESULTS formed. We first introduced age, Ca x P product, diabe-
tes, and hypercalcemia episodes as independent vari-Twenty patients had VC (4 aortic, 11 mitral, and 5 in
ables. Then, we added the other variables of the studyboth valves). Patients were grouped according to the
one by one according to Table 1. VC was independentlypresence or absence of VC. Table 1 shows that the group
influenced by age, Ca x P, and diabetes (Table 2). Thatwith VC had a significantly higher proportion of diabet-
ics, higher levels of serum phosphorus, Ca x P, and total is, for each year of increasing age, and for each unit of
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The prevalence of VC in ESRD patients is remarkably
high in all published series. Braun et al [2] reported a
VC prevalence of 50% in maintenance HD patients.
Huting et al [14] found mitral and aortic VC in 44% and
34%, respectively, in peritoneal dialysis patients. More
recently, Ribeiro et al [15] described a similar prevalence
of 44.5% and 52% of mitral and aortic calcification, re-
spectively, in dialyzed patients. Taking into account dif-
ferences in patient samples, our finding a VC prevalence
of 38.5% does not conflict with these previous reports.
There are several studies that report predictors for
cardiovascular morbidity-mortality in ESRD patients
[9, 10], but few have distinctly evaluated predictors for
VC [2, 14, 15]. Of the known factors that carry a high
risk for VC [16], mineral metabolism alteration and dysli-
pemia are modifiable, and consequently, their identifica-
tion is especially important.
Huting et al [14] observed that mitral VC was associ-Fig. 1. ROC curve for Ca x P as predictor of VC presence. The optimal
predictor cut-off value (*) was that of the highest sensitivity together ated with the severity of predialysis hypertension, high
with the lowest number of false positives. This value corresponds to Ca x P, reduced systolic function, and LV dilation. Uren˜aCa x P  43.24 mg2/dL2.
et al [4], in a multivariate analysis, found an association
between aortic stenosis and increased age, calcitriol ther-
apy, and hyperphosphatemia. Braun et al [2] reported a
increasing Ca x P, the likelihood of presenting with VC correlation between aortic VC and coronary heart dis-
increased 14% and 21%, respectively. In addition, the ease, but other comorbidities were not evaluated. Ri-
probability of VC was 4.4 times higher in diabetics when beiro et al [15] reported that mitral VC was associated
compared with nondiabetic patients, and hypercalcemia with age and high Ca x P, and aortic VC was related with
episodes (two or more episodes) presented a probability age and duration of hypertension. Summarizing these
of VC of 10.41 as compared with the absence or presence studies, elevated Ca x P always appears to be a relevant
of only one episode. The other variables were not in- risk factor for VC. Our multivariate statistical model
cluded in the equation. also showed that a high Ca x P was the strongest predictor
for VC after adjusting for comorbidities. In a secondThis same statistical model applied only to the diabetic
model, Ca x P product was substituted by serum phos-population showed that the best predictor factors for
phorus. In this model, hypercalcemia episodes, togetherVC were odds ratio (OR) and confidence interval (CI)
with hyperphosphatemia, appeared as independent pre-95%; LDL-cholesterol 1.04 [1.01–1.07], P  0.03; serum
dictors but with less statistical significance. Serum cal-phosphorus 4.6 [0.94–22.55], P  0.057; and age 1.14
cium alone was not significant in either model.[0.98–1.33], P  0.07.
Previous studies have reported a history of hyperten-The sensitivity (probability that a patient with VC
sion prior to starting dialysis as a predictor of VC [2,had Ca x P over a determined cut-off) and specificity
15, 17]. However, LVH, a consequence of long-standing(probability that a patient without VC had a Ca x P
hypertension, was not a predictor in our study. This doesbelow that cut-off) of Ca x P were calculated for different
not exclude a role for hypertension, and vigorous controlcut-off levels and are represented by ROC in Figure 1.
of blood pressure is important in this population.The best Younden’s index was 0.48 and was shared by
Regarding diabetes, we noted that this conditiontwo cut-off values of Ca x P: a Ca x P 43.2 mg2/dL2
strongly correlated with VC, but HbA1C levels did not.proved more sensitive (80%), but less specific (68.7%),
However, LDL-cholesterol appeared to be a strong pre-and a Ca x P 55.7 mg2/dL2 was less sensitive (55%),
dictor of VC. It is tempting to hypothesize that, amongbut more specific (93.7%).
diabetic patients, oxidative stress plays an important role
in the genesis of VC.
DISCUSSION Several limitations to our study should be noted. First,
This cross-sectional study showed a high prevalence it is a cross-sectional and observational study, thus, only
of VC in maintenance HD patients and an association association, and not causality, can be established. Sec-
between VC and age, diabetes, and mineral metabolism ond, the qualitative evaluation of VC (presence or ab-
abnormalities. Of note, we found Ca x P to be a strong sence) is somewhat crude; currently, more sensitive
methods provide a more accurate diagnosis of VC.predictor of VC at lower values than previously reported.
Rufino et al: Valve calcification in hemodialysis patientsS-118
5. Baglin A, Hanslik T, Vaillant JN, et al: Severe valvular heartIn spite of these limitations, our results support previ-
disease in patients on chronic dialysis. Ann Intern Med 148(8):521–
ous observations of increased prevalence of VC in ESRD 526, 1997
6. Block GA, Port FK: Re-evaluation of risks associated with hyper-patients. A Ca x P43 mg2/dL2 proved to be the optimal
phosphatemia and hyperparathyroidism in dialysis patients: Rec-value in terms of sensitivity and specificity to predict VC
ommendations for a change in management. Am J Kidney Dis
in our patient population. This value is lower than those 35(6):1226–1237, 2000
7. Goodman WG, Goldin J, Kuizon BD, et al: Coronary arterypreviously recommended in the literature to prevent VC
calcification in young adults with end-stage renal disease who arein ESRD patients [18], and is not easy to achieve in a
undergoing dialysis. N Engl J Med 18;342(20):1478–1483, 2000
clinical setting. For this reason, our findings highlight the 8. Raine AEG: Acquired aortic stenosis in dialysis patients. Nephron
68:159–168, 1994importance of more vigorous Ca x P control measures.
9. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Associa-Additional prospective controlled studies are warranted tion of serum phosphorus and calcium x phosphate product with
to confirm these observational results and to better de- mortality risk in chronic hemodialysis patients: A national study.
Am J Kidney Dis 31:607–617, 1998fine optimal Ca x P values to reduce the risk of VC in
10. Ganesh SK, Stack AG, Levin NW, et al: Association of elevatedthe maintenance HD population. serum PO4, Ca x PO(4) product, and parathyroid hormone with
cardiac mortality risk in chronic hemodialysis patients. J Am Soc
Nephrol 12(10):2131–2138, 2001ACKNOWLEDGMENT
11. Gue´rin AP, London GM, Marchais SJ, Metivier F: Arterial
stiffening and vascular calcifications in end-stage renal disease.The authors are grateful to Mr. Michael McLean for his transduction
Nephrol Dial Transplant 15:1014–1021, 2000assistance.
12. Koren MJ, Devereux RB, Casale PN, et al: Relation of left ven-
tricular mass and geometry to morbidity and mortality in uncompli-Reprint requests to Margarita Rufino Herna´ndez, C/ Ildefonso Cruz
cated essential hypertension. Ann Intern Med 114:345–352, 1991Rodrı´guez 2, Vivienda 1, 38098, Santa Cruz de Tenerife, Tenerife, Ca-
13. Devereux R, Reichek N: Echocardiographic determination of leftnary Islands, Spain.
ventricular mass in man: Anatomic validation of the method. Circu-E-mail: margaritarufino@hotmail.com
lation 55:613–618, 1997
14. Huting J: Mitral valve calcification as an index of left ventricular
dysfunction in patients with end stage renal disease on peritonealREFERENCES
dialysis. Chest 105:383–388, 1994
1. London GM, Pannier B, Marchais SJ, Guerin AP: Calcification 15. Ribeiro S, Ramos A, Brandao A, et al: Cardiac valve calcification
of the aortic valve in dialyzed patients. J Am Soc Nephrol 11:778– in haemodialysis patients: Role of calcium-phosphate metabolism.
783, 2000 Nephrol Dial Transplant 13:2037–2040, 1998
2. Braun J, Oldendorf M, Moshage W, et al: Electron beam com- 16. Cannata JB: ¿Se puede evitar el desarrollo de calcificaciones vas-
puted tomography in the evaluation of cardiac calcification in culares y cardiacas en los enfermos en dia´lisis cro´nica? Nefrologia
chronic dialysis patients. Am J Kidney Dis 27(3):394–401, 1996 XXII(Suppl 2):74–75, 2002
3. Otto CM, Lind BK, Kitzman DW, et al: Association of aortic 17. Yoshida M, Takamatsu J, Yoshida S, et al: Scores of coronary
valve sclerosis with cardiovascular mortality and morbidity in the calcification determined by electron beam computed tomography
elderly. N Engl J Med 341:112–117, 1999 are closely related to the extent of diabetes-specific complications.
4. Uren˜a P, Malergue MC, Goldfarb B, et al: Evolutive aortic Horm Metab Res 31:558–563, 1999
stenosis in hemodialysis patients: Analysis of risk factors. Nephro- 18. Dm K, Andress DL: Control of hyperphosphatemia in renal fail-
ure: Role of aluminum. Sem Dial 9:310–315, 1996logie 20:217–225, 1999
